APA (7th ed.) Citation

RL, X., C, L., L, W., AJ, C., & W, W. (2026). Three-year longitudinal assessment of denosumab's efficacy and safety in postmenopausal osteoporosis: A 36-month real-world cohort study. Frontiers in medicine, 13, 1825383. https://doi.org/10.3389/fmed.2026.1825383

Chicago Style (17th ed.) Citation

RL, Xia, Li C, Wang L, Chao AJ, and Wei W. "Three-year Longitudinal Assessment of Denosumab's Efficacy and Safety in Postmenopausal Osteoporosis: A 36-month Real-world Cohort Study." Frontiers in Medicine 13 (2026): 1825383. https://doi.org/10.3389/fmed.2026.1825383.

MLA (9th ed.) Citation

RL, Xia, et al. "Three-year Longitudinal Assessment of Denosumab's Efficacy and Safety in Postmenopausal Osteoporosis: A 36-month Real-world Cohort Study." Frontiers in Medicine, vol. 13, 2026, p. 1825383, https://doi.org/10.3389/fmed.2026.1825383.